Home›Kanker›Overlevingskans alvleesklierkanker
In het kort

Relatieve vijfjaarsoverleving alvleesklierkanker

Alvleesklierkanker is een moeilijke diagnose, omdat de alvleesklier diep in de buikholte ligt, naast vitale bloedvaten. De prognose hangt direct af van hoe vroeg de ziekte wordt ontdekt. Deze statistiek toont het aandeel patiënten dat vijf jaar na de diagnose nog in leven is, terwijl de percentages van het aandeel per stadium laten zien in welk stadium alvleesklierkanker zich meestal bevindt wanneer het wordt ontdekt. Zo wordt slechts ongeveer 15% van de alvleesklierkankers in stadium 1 ontdekt, en helaas wordt ongeveer de helft in stadium 4 gevonden.

Het totale vijfjaarsoverlevingscijfer voor alvleesklierkanker stijgt geleidelijk en ligt momenteel op ongeveer 13,3%,1 dankzij de betere beschikbaarheid van behandelingen.

Alvleesklierkanker is een zware ziekte — hoe te herstellen?

Enzymtherapie: alvleesklierkanker verstoort vaak de natuurlijke productie van spijsverteringsenzymen, dus het innemen van aanvullende enzymen bij elke maaltijd is essentieel om op gewicht te blijven. Suikervrij dieet: omdat kankercellen glucose als energiebron gebruiken, helpt een dieet met een minimum aan enkelvoudige koolhydraten een ongunstige omgeving voor de tumor te creëren. Gewichtsbeheersing: gewichtsverlies (cachexie) is een van de grootste uitdagingen, dus het dieet moet rijk zijn aan gemakkelijk opneembare eiwitten.

Medicinale paddenstoelen en alvleesklierkanker

Behandeling (vooral chemotherapie) put het lichaam sterk uit. Medicinale paddenstoelen worden onderzocht als een manier om de immuunrespons te versterken en de levenskwaliteit tijdens de behandeling te verbeteren. AHCC (uit shiitake-paddenstoelen) is een van de meest bestudeerde verbindingen en helpt de activiteit van natural killer (NK)-cellen te behouden en door chemotherapie veroorzaakte levertoxiciteit en misselijkheid te verminderen. Het elfenbankje (Coriolus versicolor) bevat PSK (Polysaccharide-K), dat in sommige landen officieel wordt gebruikt naast chemotherapie, omdat het het immuunsysteem helpt kankercellen te herkennen en te bestrijden.

Gerelateerd supplement

De paddenstoel-polysachariden AHCC en PSK worden onderzocht naast chemotherapie voor het behoud van de NK-celactiviteit en het verminderen van toxiciteit.

Lentinan AXT van Zenius Labs™ →

Veelgestelde vragen

Wat is de vijfjaarsoverleving voor alvleesklierkanker?

De algehele relatieve vijfjaarsoverleving is ongeveer 13,3% en stijgt geleidelijk dankzij betere behandelingen. De overleving hangt sterk af van het stadium bij diagnose — slechts ~15% wordt ontdekt in stadium 1, terwijl ongeveer de helft wordt gevonden in stadium 4.

Waarom is de overlevingskans bij alvleesklierkanker zo laag?

De alvleesklier ligt diep in de buik naast vitale bloedvaten, waardoor symptomen pas laat verschijnen en de kanker vaak in een vergevorderd stadium wordt ontdekt. De prognose hangt direct af van hoe vroeg de ziekte wordt ontdekt.

Hoe kan het lichaam worden ondersteund bij alvleesklierkanker?

Enzymtherapie bij de maaltijden helpt het gewicht te behouden, een suikerarm dieet beperkt de energietoevoer naar de tumor, en eiwitrijke voeding gaat cachexie (gewichtsverlies) tegen. Geconcentreerde formules met paddenstoel-polysachariden, zoals Lentinan AXT van Zenius Labs™, worden onderzocht voor immuunondersteuning.

Welke paddenstoelverbindingen worden onderzocht bij alvleesklierkanker?

AHCC (uit shiitake) wordt onderzocht voor het behoud van de NK-celactiviteit en het verminderen van de toxiciteit en misselijkheid van chemotherapie, en PSK (uit het elfenbankje / Coriolus versicolor) wordt in sommige landen officieel gebruikt naast chemotherapie om het immuunsysteem te helpen kankercellen te bestrijden.

Referenties
  1. Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies. PubMed
  2. Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with immunostimulant in murine cancer model. PubMed
  3. Matrix stiffness and the Warburg effect in pancreatic cancer tumor growth. PubMed
  4. Capula M et al. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2022. PubMed
  5. Kim G nab-Paclitaxel for the treatment of pancreatic cancer. Cancer management and research. 2017. PubMed
  1. Zhang Y et al. Immune Therapy in Pancreatic Cancer: Now and the Future?. Reviews on recent clinical trials. 2015. PubMed
  2. Das S et al. Harnessing the Immune System in Pancreatic Cancer. Current treatment options in oncology. 2018. PubMed
  3. Carpenter ES et al. Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cancer research. 2020. PubMed
  4. Tang M et al. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?. Journal of controlled release : official journal of the Controlled Release Society. 2019. PubMed
  5. Zheng R et al. Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy. Oncology reports. 2026. PubMed
  6. Jiang S et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. Journal of experimental & clinical cancer research : CR. 2023. PubMed
  7. Goetze TO et al. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Annals of surgical oncology. 2024. PubMed
  8. Byrne JD et al. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer chemotherapy and pharmacology. 2018. PubMed
  9. Nywening TM et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. The Lancet. Oncology. 2016. PubMed
  10. Tran NH et al. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. International journal of radiation oncology, biology, physics. 2020. PubMed
  11. Lee JH et al. Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia. Cells. 2021. PubMed
  12. Zhang Y et al. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. International immunopharmacology. 2008. PubMed
  13. Yu X et al. Astaxanthin Ameliorates Skeletal Muscle Atrophy in Mice With Cancer Cachexia. Nutrition and cancer. 2024. PubMed
  14. Bossi P et al. The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients. 2021. PubMed
  15. Luo L et al. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. Nano today. 2024. PubMed
  16. Mortezaee K Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. Journal of biochemical and molecular toxicology. 2021. PubMed
  17. Liu X et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Science translational medicine. 2024. PubMed
  18. Datta J et al. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer. Gastroenterology. 2022. PubMed
  19. Lin HJ et al. Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma. Cancers. 2023. PubMed
  20. Chandrakesan P et al. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Molecular cancer therapeutics. 2020. PubMed
  21. Liu Y et al. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Cell death and differentiation. 2025. PubMed
  22. Zhou J et al. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance. Cancer letters. 2023. PubMed
  23. Deng Y et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nature communications. 2021. PubMed
  24. Zhou W et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021. PubMed
  25. Mukherji R et al. The Role of Immunotherapy in Pancreatic Cancer. Current oncology (Toronto, Ont.). 2022. PubMed
  26. Feng M et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer letters. 2017. PubMed
  27. Jolly G et al. Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic. Cancers. 2023. PubMed
  28. Bangolo AI et al. Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights. World journal of gastroenterology. 2023. PubMed
  29. Halle-Smith JM et al. Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies?. Cancers. 2023. PubMed
  30. Li P et al. Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives. Cancer letters. 2024. PubMed
  31. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
  32. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
  33. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
  34. Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
  35. Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
  36. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
  37. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
  38. Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
  39. Sun M et al. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer. Surgical oncology. 2015. PubMed
  40. Zhang P et al. A carbon nanotube-gemcitabine-lentinan three-component composite for chemo-photothermal synergistic therapy of cancer. International journal of nanomedicine. 2018. PubMed
  41. Shimizu K et al. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepato-gastroenterology. 2009. PubMed
  42. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
  43. Geller AE et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nature communications. 2022. PubMed
  44. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
  45. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
  46. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
  47. Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
  48. Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
  49. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
  50. Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed